Atjaunināt sīkdatņu piekrišanu

From Radiobiology to Radiation Oncology [Hardback]

Edited by , Edited by , Edited by , Edited by
  • Formāts: Hardback, 440 pages, height x width: 235x155 mm, 13 Illustrations, color; 2 Illustrations, black and white; II, 440 p. 15 illus., 13 illus. in color., 1 Hardback
  • Izdošanas datums: 11-Sep-2025
  • Izdevniecība: Springer International Publishing AG
  • ISBN-10: 3031957237
  • ISBN-13: 9783031957239
Citas grāmatas par šo tēmu:
  • Hardback
  • Cena: 180,78 €*
  • * ši ir gala cena, t.i., netiek piemērotas nekādas papildus atlaides
  • Standarta cena: 212,69 €
  • Ietaupiet 15%
  • Grāmata tiks piegādāta 3-6 nedēļas pēc tās publicēšanas.
  • Daudzums:
  • Ielikt grozā
  • Piegādes laiks - 4-6 nedēļas
  • Pievienot vēlmju sarakstam
From Radiobiology to Radiation Oncology
  • Formāts: Hardback, 440 pages, height x width: 235x155 mm, 13 Illustrations, color; 2 Illustrations, black and white; II, 440 p. 15 illus., 13 illus. in color., 1 Hardback
  • Izdošanas datums: 11-Sep-2025
  • Izdevniecība: Springer International Publishing AG
  • ISBN-10: 3031957237
  • ISBN-13: 9783031957239
Citas grāmatas par šo tēmu:
This book offers a wide perspective on the fundamental and state-of-the-art knowledge in radiobiology, radiation oncology, and the connection between both fields. Chapters incorporate basic concepts of cancer biology and radiobiology with advances in radiotherapy in cancer treatment for various types of cancer. Chapters review one or more areas of radiation oncology with topics ranging from the application of radiotherapy in various cancers, the use of advanced techniques such as FLASH radiotherapy, applications of artificial intelligence in treatment planning, and more importantly, the current and potential strategies to reduce the toxic effects of radiation. This book incorporates interdisciplinary concepts by exploring recent approaches like radiogenomics for personalizing radiotherapy and the effects of the microbiome on radiation research.



Teaching the basics of radiobiology and connections between the theory and the practical aspects of radiotherapy techniques, this book is a useful reference for cancer researchers, practitioners, interdisciplinary researchers in related fields, and students in radiation oncology and radiobiology. Through this integration of strong scientific foundations and clinical applicability, this book provides future research directions and rationales for readers looking to expand their knowledge about radiation with the most recent and essential data on the subject.
1. Overview on Cancer Biology and cancer hallmarks.- 2. Introduction to
Seven Rs of Radiobiology.-
3. Radiosensitivity and its contributing
biologic factors.-
4. Innovative Strategies to Enhance Radiosensitivity:
Hyperthermia, Nanoparticles, and DNA Repair Inhibition.-
5. Role of
Tumor-Initiating Stem Cells in Tumor Resistance and Relapse.-  6. Cancer
Cells Fates upon Radiation.-
7. Overview of Radiotherapy Techniques and
Modalities: Conventional and Modern Approaches.-  8. Recent Advances in
Radiotherapy of Breast cancer.-  Chapter 9 Advances in Radiotherapy of
Gastrointestinal Cancers.-  10. Recent Advances in Radiotherapy of Lung
Cancer.-  11. Advances in Radiotherapy of Genitourinary Cancers.-  12.
Advances in Radiotherapy of Brain Tumors.-  13.  Advances in Head and Neck
Cancer.-
14. Application of radiotherapy in oligometastatic disease.-  15.
Emerging Role of FLASH Radiotherapy.-
16. Novel Approaches to Counteract
Radiotherapy Toxicities: Focusing on Radioprotectors and Radiation
Mitigators.-
17. Advances in Radiotherapy using Artificial Intelligence.-
18.
Radiogenomics: A Potential Approach for Personalized radiotherapy.
19. The
Emerging role of Microbiome in Radiation Research.-
20. Future Directions in
Radiobiology and Clinical Radiation Oncology.
Dr. Farzad Taghizadeh-Hesary, M.D., is an Assistant Professor of Radiation Oncology at the Iran University of Medical Sciences. His research and clinical expertise lie at the intersection of radiation oncology, radiobiology, and cancer metabolism. Dr. Taghizadeh-Hesary's work focuses on integrating the tumor microenvironment and mitochondrial metabolism into cancer research and personalized radiotherapy. He has published over 90 peer-reviewed articles in high-impact journals and serves on the editorial boards of leading oncology journals. Dr. Taghizadeh-Hesary has received numerous awards, including the prestigious Razi Medical Science Research Prize. With a deep understanding of the complex interplay between radiation, tumor biology, and metabolic pathways, Dr. Taghizadeh-Hesary's work aims to develop innovative strategies for improving cancer treatment outcomes and enhancing the quality of life for patients.



Sumel Ashique has been working as an assistant professor at Department of Pharmaceutical Technology, Bharat Technology, Uluberia-711316, West Bengal, India. He has knowledge in drug delivery, nanotechnology and targeted treatment strategy. Currently he has edited 18+ books under CRC Press, Taylor and Francis, Wiley, Nova Science and Springer.



Dr. Neeraj Mishra is working as Professor in Amity Institute of Pharmacy, Gwalior since July 2019. He has around twenty years of teaching and research experience. He has more than 100 publications of International and National repute in recent concepts of novel drug delivery systems, localized drug delivery, targeted and controlled drug delivery of nanocarriers/ microparticles for the treatment of breast, colon cancer, and neurodegenerative disorders.



Dr. Babak Behnam is a Research Professor in biology and genomic medicine at American University and Floret Genomic Center. His research interests focus on molecular metastatic pathway and cancer/mitochondrial biology. Previously, he served as Associate Professor of Human Genetics at Iran University of Medical Sciences (IUMS) and established/directed the medical genetics laboratory at OB/G and Childrens University Hospitals. Returning to the U.S., he joined the Undiagnosed Disease Program at NIH while completing an ABMGG-accredited fellowship in clinical biochemical genetics at NHGRI. He later transitioned to Regulatory Affairs at NSF International, managing FDA submissions and compliance. As co-founder and CSO of Avicenna Biotech Research, he drives IP strategy and serves as a MSL. An active academic contributor, he serves on the editorial boards of MDPI Cancers and Frontiers, and holds multiple patents in addiction therapies and cancer therapeutics.